Israel Englander’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-140,595
| Closed | -$2.75M | – | 6449 |
|
|
2026
Q1 | $2.75M | Sell |
140,595
-319,530
| -69% | -$9.49M | ﹤0.01% | 3554 |
|
|
2025
Q4 | $14.3M | Buy |
460,125
+323,845
| +238% | +$8.88M | 0.01% | 1896 |
|
|
2025
Q3 | $2.94M | Buy |
136,280
+76,844
| +129% | +$1.39M | ﹤0.01% | 3682 |
|
|
2025
Q2 | $831K | Sell |
59,436
-238,530
| -80% | -$3.24M | ﹤0.01% | 4547 |
|
|
2025
Q1 | $4.02M | Sell |
297,966
-68,006
| -19% | -$1.16M | ﹤0.01% | 3078 |
|
|
2024
Q4 | $7.02M | Sell |
365,972
-302,064
| -45% | -$6.57M | ﹤0.01% | 2499 |
|
|
2024
Q3 | $15.2M | Buy |
668,036
+439,854
| +193% | +$7.19M | 0.01% | 1811 |
|
|
2024
Q2 | $2.97M | Buy |
228,182
+207,711
| +1,015% | +$2.88M | ﹤0.01% | 3181 |
|
|
2024
Q1 | $358K | Sell |
20,471
-204,318
| -91% | -$3.96M | ﹤0.01% | 5029 |
|
|
2023
Q4 | $4.9M | Sell |
224,789
-1,155,861
| -84% | -$18.2M | ﹤0.01% | 2808 |
|
|
2023
Q3 | $21.2M | Buy |
1,380,650
+42,862
| +3% | +$818K | 0.01% | 1394 |
|
|
2023
Q2 | $31.8M | Buy |
1,337,788
+723,699
| +118% | +$18.6M | 0.02% | 1039 |
|
|
2023
Q1 | $15.6M | Sell |
614,089
-171,765
| -22% | -$5.51M | 0.01% | 1547 |
|
|
2022
Q4 | $23M | Buy |
785,854
+23,794
| +3% | +$548K | 0.01% | 1330 |
|
|
2022
Q3 | $15.6M | Sell |
762,060
-364,025
| -32% | -$6.54M | 0.01% | 1608 |
|
|
2022
Q2 | $13M | Buy |
1,126,085
+150,467
| +15% | +$2.02M | 0.01% | 1729 |
|
|
2022
Q1 | $18M | Buy |
975,618
+513,228
| +111% | +$9.86M | 0.01% | 1493 |
|
|
2021
Q4 | $9.14M | Buy |
462,390
+301,045
| +187% | +$5.61M | ﹤0.01% | 2234 |
|
|
2021
Q3 | $2.65M | Buy |
161,345
+43,630
| +37% | +$640K | ﹤0.01% | 3577 |
|
|
2021
Q2 | $2.15M | Buy |
117,715
+74,539
| +173% | +$1.28M | ﹤0.01% | 3872 |
|
|
2021
Q1 | $721K | Buy |
+43,176
| New | +$808K | ﹤0.01% | 4509 |
|
|
2020
Q2 | – | Sell |
-916
| Closed | -$6K | – | 4631 |
|
|
2020
Q1 | $6K | Sell |
916
-11,077
| -92% | -$129K | ﹤0.01% | 3765 |
|
|
2019
Q4 | $86K | Sell |
11,993
-14,724
| -55% | -$151K | ﹤0.01% | 4046 |
|
|
2019
Q3 | $292K | Sell |
26,717
-12,947
| -33% | -$286K | ﹤0.01% | 3586 |
|
|
2019
Q2 | $1.22M | Buy |
39,664
+34,984
| +748% | +$1.4M | ﹤0.01% | 2686 |
|
|
2019
Q1 | $196K | Buy |
+4,680
| New | +$212K | ﹤0.01% | 3743 |
|
|
2018
Q4 | – | Sell |
-5,916
| Closed | -$495K | – | 4212 |
|
|
2018
Q3 | $495K | Sell |
5,916
-1,962
| -25% | -$185K | ﹤0.01% | 3263 |
|
|
2018
Q2 | $758K | Buy |
7,878
+3,991
| +103% | +$422K | ﹤0.01% | 2979 |
|
|
2018
Q1 | $409K | Buy |
+3,887
| New | +$422K | ﹤0.01% | 3090 |
|
|
2017
Q2 | – | Sell |
-4,347
| Closed | -$811K | – | 3904 |
|
|
2017
Q1 | $811K | Buy |
+4,347
| New | +$750K | ﹤0.01% | 2529 |
|
Other funds holding VRDN
BG
PBA
KCM
FFM
DTC
Israel Englander's VRDN Position: Q2 2026 in Review
Israel Englander sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 140,595 shares — an estimated $2.75M sold.
Israel Englander first reported a position in VRDN in Q1 2017 and held it in 30 quarters. The position peaked at $31.8M in Q2 2023. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.
- Israel Englander reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
- Israel Englander sold 140,595 Viridian Therapeutics shares in Q2 2026, an estimated $2.75M.
- Israel Englander first reported a position in Viridian Therapeutics in Q1 2017 and held it in 30 quarters.
- Israel Englander's Viridian Therapeutics position peaked at $31.8M in Q2 2023.
- 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.